drugset
drugset / Trial / NCT00374868

Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)

NCT00374868 ↗

Phase 1/2 Completed 59 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the anti-tumor activity, as measured by response rate to bi-weekly pemetrexed plus cisplatin, in chemo-naive patients with diagnosed metastatic or locally advanced (non-resectable) urothelial cancer.

Timeline

Start
2006-08
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 50 mg/m2 Intravenous
Subject Pemetrexed Small molecule 300 mg/m2 Intravenous
Subject Pemetrexed Small molecule 400 mg/m2 Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

urothelial carcinoma